Biobanking Conference 2010

Biobanking Conference 2010
Analysing the trends and understanding the complexities of biobanking
4th - 5th February 2010, Earls Court Conference Centre, London, UK

Background Info

Key Speakers

• Julie Corfield, R&D Site Biobank Head, Astrazeneca
• Anne Bahr, R&D Data Privacy Coordinator, Sanofi-Aventis
• Dr. Maria Krestyaninova, Biomedical Informatics Coordinator, European Bioinformatics Institute
• Dr. Kristian Unger, Research Associate Division of Investigative Science, Imperial College London
• Kate Rolfvondenbaumen, Regulation Manager, Human Tissue Authority
• Dr. Alison Parry-Jones, Manager, Wales Cancer Bank
• Marc Martens, Partner, Bird & Bird LLP
• Morag McFarlane, Chief Scientific Officer, Tissue Solutions
• Dr. John Cason, Senior (Non-Clinical) Lecturer in Virology, King’s College London School of Medicine
• Dr. Michael D. Leek, Vice President, The Weinberg Group

Biobanking is changing rapidly. Biobanks are playing a vital role in today’s research and development in the fields of drug discovery and bioscience. The biobanking sector has expanded at a tremendous rate in recent years, and has also been facing many legal, financial, ethical, scientific challenges.

Happy to announce its inaugural Biobanking Conference which will examine major trends in the biobanking industry and its changing scope. By attending Biobanking conference delegates will gain an in-depth understanding of the emerging opportunities, challenges and advancements made in the field of biobanking.

Why Attend?

Key benefits
• Assess the increasing need for developing biobanks
• Understand the ethical and regulatory issues
• Implement strategies to develop a cost-effective biobank
• Examine the importance of patient involvement in biobank projects
• Learn about data protection and quality management in biobanking
• Discuss most acute and challenging scientific and policy related matters
• Seize this opportunity to network with leaders from pharma-biotech, healthcare and regulatory agencies

Who should attend?

VPs, Directors, Heads, Managers of:
• Biobank
• Tissue bank
• Biorepository
• Molecular Diagnostics
• Clinical Genetics, Pathology
• Histopathology
• Medical Genomics
• Non-clinical Biosample
• Data Privacy Office
• Health Science Policy
• Scientific and Quality
• Toxicology, Clinical chemistry
• Laboratory and Inventory
• R&D
• Quality Control
• Pharmacogenomics
• Procurement and Strategic Sourcing
• Strategic Outsourcing
• Clinical Research
• Translational Medicine
• Personalized Medicine,
• Bioanalytical Chemistry
• Clinical trials and Non-clinical R & D
• Pharmacogenomics
• Proteomics
• Personalised medicine
• Business development
• Strategic alliances

Others:
• Consultants& Academics
• Regulatory bodies
• Researchers

Day 1

Day 1, Thursday 4th February 2010, London, UK

09:30 Registration and refreshments

10:00 Opening address from the chair

BIOBANKING - WHERE IS IT HEADING?

10:10 Biobanking in 2010
• Analysing the current biobanking landscape
• Recent advancements in sample collection and processing
• Perspective on future initiatives in biobanking

Derick Mitchell
Executive Manager
BBMRI*

10:50 Biobanking to sustain R&D in pharma
• General aspects-purpose and scope
• A-Z perspective of establishing a biobank
• Challenges and needs

Julie Corfield
R&D Site Biobank Head
Astrazeneca

11:30 Morning refreshments

11:50 Presentation to be announced

12:30 Utilising retrospective versus prospective samples for research- the hurdles and challenges
• Legal, ethical and consent requirements
• Harmonisation of sample handling/processing and QA systems
• Clinical information/matched samples - requirements vs reality
• Cost and time implications

Morag McFarlane
Chief Scientific Officer
Tissue Solutions

13:10 Networking lunch

WHAT ARE THE CHALLENGES?

14:30 Biobanking: an attempt at a global regulatory approach
• Typology of biobanks and their respective regulatory framework
• Current legal issues in biobanking (privacy issues, ownership rights, informed consent, etc.)
• Import and export of biobanking materials: a need for harmonisation?

Marc Martens
Partner
Bird & Bird LLP

15:10 Challenges for the governance of biobanks
• The mixed message of regulatory bodies: ‘dangers’ and ‘profits’
• The challenge for biobankers: answering the message bottom-up with their governance strategy
• Transparency to the public and patients, avoiding unwarranted expectations
• How to deal with the feed-back issue? (of individual results to participants)
• The traditional view and the good reasons for this view
• Should GWAS change the traditional view of (non) individual feed-back?
• Should GWAS and international cooperation change the traditional view of the promise of privacy?
• The continuous dialogue with stakeholders
• Governance as self-regulation and an investment in trust

Evert-Ben van Veen
Director
Medlawconsult

15:50 Afternoon Refreshments

16:10 Presentation to be announced

Kate Rolfvondenbaumen
Regulation Manager
Human Tissue Authority

16:50 QA in biobanking and its importance for the generation of experimental data
• QA of issued tissue/ biobanking material has a high impact on the potential of cancer biomarker research
• QA checkpoints in the process of tissue collection and extractions are controlled by using SOPs (standard operation protocols)
• Controlled specimen quality maximises the usability of clinical specimens in terms of the number of potential users and applications and the quality of the resulting data
• The maximum average quality of biobanking material is tissue-specific
• Examples for techniques well applicable on low-quality RNA: MicroRNA and qRT-PCR
• Multiplex PCR – an approach to control the influence of DNA quality on the quality of array copy number data
• Demonstration of the influence of DNA quality on data quality and how bioinformatics deals with the problem

Dr. Kristian Unger
Research Associate Division of Investigative Science
Imperial College London

17:30 Closing remarks from the chair

17:40 Networking drinks
Take your discussions further and build new relationships in a relaxed and informal setting

Day 2

Day 2, Friday 5th February 2010, London, UK

09:30 Registration and refreshments

10:00 Opening address from the chair

10:10 Learn about data protection in biobanking
• Personal Data Protection: The main principles
• How can samples from clinical studies be re-used for research?
• Informed consent in practice: Specificities imposed by French, Italian and Spanish authorities
• Standardising practices: What level is possible in a multinational pharmaceutical company?

Anne Bahr
R&D Data Privacy Coordinator
Sanofi Aventis

10:50 SIMBioMS_ - IT solutions for data collection, harmonisation and analysis in large-scale biomedical genomics projects
• Handling and combining sample data (SIMS), assays and measurement data from a wide range of technologies (AIMS), and for browsing, summarizing and annotating its complex data content (SAIL)
• Provides support for multi-partner biomedical data management from the moment of study design to the data analysis
• Sample annotation and tracking, sample size estimation in cross-collection meta-studies, genetic and molecular data consistency, and practical aspects of data standardisation and harmonisation in collaborative discovery projects

Dr. Maria Krestyaninova
Biomedical Informatics Coordinator
European Bioinformatics Institute

11:30 Morning refreshments

RECENT CASE STUDIES

11:50 The infectious diseases biobank at King’s College London: Facilitating translational research of pathogens
• Local need for the resource
• BioBank organisation and operation
• Outcomes
• Future challenges

Dr. John Cason
Senior (Non-Clinical) Lecturer in Virology
King’s College London School of Medicine

12:30 Wales Cancer Bank- Experiences of formulating an access policy and issuing samples to the research community
• What will be made available? Sample availability and processing
• Deciding on an appropriate access policy
• Mechanisms to ensure transparency
• Charging for samples
• Material transfer agreements
• Logistics and training

Dr. Alison Parry-Jones
Manager
Wales Cancer Bank

13:10 Networking lunch

14:30 Biomarkers as a tool for personalised medicine
• Analysing the opportunities, challenges, approaches
• Discussing recent developments

Alastair Kent
Director
Genetic Interest Group*

15:10 Assessing principles and practices of genetic biobanking studies

Nigel Spurr
Roche*

15:50 Afternoon refreshments

FUTURE PERSPECTIVES

16:10 Commercialisation challenges
• Analysing quality and logistic issues
• Discussing regulatory issues related to commercialisation of stem cells from biobanks

Dr. Michael D. Leek
Vice President
The Weinberg Group

16:50 Public attitudes to tissue and organ donation
• Methods of engaging the public on complex and sensitive issues
• Results from several OL research projects relating to tissue and organ donation

Becky Seale
Consultant
Opinion Leader

17:30 Chair’s closing remarks

17:40 End of Conference

Related Reports:

The Future of Biobanks: Regulation, ethics, investment and the humanization of drug discovery
Lux Biosciences Inc Product Pipeline Analysis
Ardea Biosciences, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Biotech 2008 Life Sciences: A 20/20 Vision to 2020